Саудовская Аравия - английский - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

pfizer europe ma eeig, belgium - rituximab - concentrate for solution for infusion - 10 mg/ml,

Саудовская Аравия - английский - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

pfizer europe ma eeig, belgium - polysaccharide for serotypes 1, 3, 4, 5, 6a, 7f, 8, 9v, 10, 11a, 12f, 14, 15b, 18c, 19a, 19f, 22f, 23f, 33f,polysaccharide for serotypes 6b,crm197 protein - suspension for injection - 2.2,4.4,51 µg,

Саудовская Аравия - английский - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

pfizer europe ma eeig, belgium - polysaccharide for serotypes 1, 3, 4, 5, 6a, 7f, 8, 9v, 10, 11a, 12f, 14, 15b, 18c, 19a, 19f, 22f, 23f, 33f,polysaccharide for serotypes 6b,crm197 protein - suspension for injection - 2.2,4.4,51 µg,

Саудовская Аравия - английский - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

pfizer europe ma eeig, belgium - rsv subgroup a stabilised prefusion f,rsv subgroup b stabilised prefusion f - powder and solvent for solution for injection - 60,60 µg,

Саудовская Аравия - английский - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

pfizer europe ma eeig, belgium - rsv subgroup a stabilised prefusion f,rsv subgroup b stabilised prefusion f - powder and solvent for solution for injection - 60,60 µg,

Соединенные Штаты - английский - NLM (National Library of Medicine)

pfizer manufacturing belgium nv - tozinameran (unii: 5085zfp6sj) (tozinameran - unii:5085zfp6sj) - pfizer-biontech covid-19 vaccine is authorized for use under an emergency use authorization (eua) for active immunization to prevent coronavirus disease 2019 (covid-19) caused by severe acute respiratory syndrome coronavirus 2 (sars-cov-2) in individuals 6 months of age and older. this eua prescribing information pertains only to pfizer-biontech covid-19 vaccine supplied in a multiple dose vial with a purple cap, which is authorized for use in individuals 12 years of age and older. do not administer pfizer-biontech covid-19 vaccine to individuals with known history of a severe allergic reaction (e.g., anaphylaxis) to any component of the pfizer-biontech covid-19 vaccine [see description (13)] . risk summary all pregnancies have a risk of birth defect, loss, or other adverse outcomes. in the us general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. available data on pfizer-biontech covid-19 vaccine

Соединенные Штаты - английский - NLM (National Library of Medicine)

pfizer manufacturing belgium nv - tozinameran (unii: 5085zfp6sj) (tozinameran - unii:5085zfp6sj) - pfizer-biontech covid-19 vaccine and pfizer-biontech covid-19 vaccine, bivalent (original and omicron ba.4/ba.5) are authorized for use under an emergency use authorization (eua) for active immunization to prevent coronavirus disease 2019 (covid-19) caused by severe acute respiratory syndrome coronavirus 2 (sars-cov-2) in individuals 6 months of age and older. this eua prescribing information pertains only to pfizer-biontech covid-19 vaccine and pfizer-biontech covid-19 vaccine, bivalent (original and omicron ba.4/ba.5), hereafter referred to as pfizer-biontech covid-19 vaccine, bivalent, supplied in multiple dose vials with maroon caps and labels with maroon borders, which are authorized for use in individuals 6 months through 4 years of age. do not administer pfizer-biontech covid-19 vaccine or pfizer-biontech covid-19 vaccine, bivalent to individuals with known history of a severe allergic reaction (e.g., anaphylaxis) to any component of the pfizer-biontech covid-19 vaccine [see description (13)] .       p

Соединенные Штаты - английский - NLM (National Library of Medicine)

pfizer manufacturing belgium nv - tozinameran (unii: 5085zfp6sj) (tozinameran - unii:5085zfp6sj) - pfizer-biontech covid-19 vaccine is authorized for use under an emergency use authorization (eua) for active immunization to prevent coronavirus disease 2019 (covid-19) caused by severe acute respiratory syndrome coronavirus 2 (sars-cov-2) in individuals 6 months of age and older. this eua prescribing information pertains only to pfizer-biontech covid-19 vaccine supplied in a multiple dose vial with a gray cap and label with a gray border, which is authorized for use in individuals 12 years of age and older. do not administer pfizer-biontech covid-19 vaccine to individuals with known history of a severe allergic reaction (e.g., anaphylaxis) to any component of the pfizer-biontech covid-19 vaccine [see description (13)] . risk summary all pregnancies have a risk of birth defect, loss, or other adverse outcomes. in the us general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. available data on pfizer

Соединенные Штаты - английский - NLM (National Library of Medicine)

pfizer manufacturing belgium nv - tozinameran (unii: 5085zfp6sj) (tozinameran - unii:5085zfp6sj) - pfizer-biontech covid-19 vaccine is authorized for use under an emergency use authorization (eua) for active immunization to prevent coronavirus disease 2019 (covid-19) caused by severe acute respiratory syndrome coronavirus 2 (sars-cov-2) in individuals 6 months of age and older. this eua prescribing information pertains only to pfizer-biontech covid-19 vaccine supplied in a multiple dose vial with an orange cap and a label with an orange border, which is authorized for use in individuals 5 through 11 years of age. the vial labels state: age 5y to <12y. the carton labels state: for age 5 years to <12 years. do not administer pfizer-biontech covid-19 vaccine to individuals with known history of a severe allergic reaction (e.g., anaphylaxis) to any component of the pfizer-biontech covid-19 vaccine [see description (13)] . risk summary all pregnancies have a risk of birth defect, loss, or other adverse outcomes. in the us general population, the estimated background risk of major birth defects and miscarriage i

Соединенные Штаты - английский - NLM (National Library of Medicine)

pfizer manufacturing belgium nv - tozinameran (unii: 5085zfp6sj) (tozinameran - unii:5085zfp6sj), famtozinameran (unii: jsv288q5cv) (famtozinameran - unii:jsv288q5cv) - pfizer-biontech covid-19 vaccine, bivalent (original and omicron ba.4/ba.5) is authorized for use under an emergency use authorization (eua) for active immunization to prevent coronavirus disease 2019 (covid-19) caused by severe acute respiratory syndrome coronavirus 2 (sars-cov-2) in individuals 12 years of age and older. this eua prescribing information pertains only to pfizer-biontech covid-19 vaccine, bivalent (original and omicron ba.4/ba.5), hereafter referred to as pfizer-biontech covid-19 vaccine, bivalent. do not administer pfizer-biontech covid-19 vaccine, bivalent to individuals with known history of a severe allergic reaction (e.g., anaphylaxis) to any component of the pfizer-biontech covid-19 vaccine or the pfizer-biontech covid-19 vaccine, bivalent [see description (13)] . risk summary no data are available regarding the use of pfizer-biontech covid-19 vaccine, bivalent during pregnancy. all pregnancies have a risk of birth defect, loss, or other adverse outcomes. in the us general population, t